|
Name |
Methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate
|
Molecular Formula | C16H16O5 | |
IUPAC Name* |
methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate
|
|
SMILES |
CC1=CC(=CC(=C1)OC2=CC(=C(C(=C2)C)C(=O)OC)O)O
|
|
InChI |
InChI=1S/C16H16O5/c1-9-4-11(17)7-12(5-9)21-13-6-10(2)15(14(18)8-13)16(19)20-3/h4-8,17-18H,1-3H3
|
|
InChIKey |
YAIYRXPNTQJXBE-UHFFFAOYSA-N
|
|
Synonyms |
4-Methoxycarbonyldiorcinol; CHEMBL2332158; methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate; 4-(3-Hydroxy-5-methylphenoxy)-2-methyl-6-hydroxybenzoic acid methyl ester
|
|
CAS | NA | |
PubChem CID | 71719401 | |
ChEMBL ID | CHEMBL2332158 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 288.29 | ALogp: | 3.9 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 76.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 21 | QED Weighted: | 0.833 |
Caco-2 Permeability: | -4.982 | MDCK Permeability: | 0.00001950 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.863 |
30% Bioavailability (F30%): | 0.185 |
Blood-Brain-Barrier Penetration (BBB): | 0.082 | Plasma Protein Binding (PPB): | 99.16% |
Volume Distribution (VD): | 0.583 | Fu: | 1.38% |
CYP1A2-inhibitor: | 0.97 | CYP1A2-substrate: | 0.877 |
CYP2C19-inhibitor: | 0.909 | CYP2C19-substrate: | 0.092 |
CYP2C9-inhibitor: | 0.733 | CYP2C9-substrate: | 0.945 |
CYP2D6-inhibitor: | 0.892 | CYP2D6-substrate: | 0.846 |
CYP3A4-inhibitor: | 0.695 | CYP3A4-substrate: | 0.186 |
Clearance (CL): | 12.434 | Half-life (T1/2): | 0.841 |
hERG Blockers: | 0.056 | Human Hepatotoxicity (H-HT): | 0.061 |
Drug-inuced Liver Injury (DILI): | 0.518 | AMES Toxicity: | 0.1 |
Rat Oral Acute Toxicity: | 0.177 | Maximum Recommended Daily Dose: | 0.955 |
Skin Sensitization: | 0.805 | Carcinogencity: | 0.612 |
Eye Corrosion: | 0.019 | Eye Irritation: | 0.978 |
Respiratory Toxicity: | 0.752 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005402 | 0.790 | D07MGA | 0.283 | ||||
ENC000979 | 0.677 | D0Y7PG | 0.276 | ||||
ENC004713 | 0.657 | D06GCK | 0.273 | ||||
ENC002783 | 0.653 | D0H2ZW | 0.269 | ||||
ENC005290 | 0.577 | D0S6JG | 0.266 | ||||
ENC002445 | 0.576 | D04AIT | 0.264 | ||||
ENC003724 | 0.569 | D03TPR | 0.260 | ||||
ENC004643 | 0.556 | D06RGG | 0.260 | ||||
ENC000729 | 0.542 | D0B0AX | 0.245 | ||||
ENC003748 | 0.527 | D0A1DH | 0.245 |